

Available online at www.sciencedirect.com



Bioorganic & Medicinal Chemistry Letters

Bioorganic & Medicinal Chemistry Letters 17 (2007) 3398-3401

Synthesis and evaluation of 2'-substituted cyclobutyl nucleosides and nucleotides as potential anti-HIV agents

Yongfeng Li,^a Shuli Mao,^a Michael W. Hager,^a Kimberlynne D. Becnel,^a Raymond F. Schinazi^b and Dennis C. Liotta^{a,*}

^aDepartment of Chemistry, Emory University, Atlanta, GA 30322, USA

^bDepartment of Pediatrics, Laboratory of Biochemical Pharmacology, Veterans Affairs Medical Center, Emory University School of Medicine, Decatur, GA 30033, USA

> Received 10 February 2007; revised 19 March 2007; accepted 29 March 2007 Available online 3 April 2007

Abstract—A series of 2'-substituted cyclobutyl nucleoside analogs were efficiently prepared by constructing the core cyclobutyl ring using different [2+2] cycloaddition approaches. The triphosphate derivative of a cyclobutyl nucleoside was also synthesized and evaluated against wild-type and mutant HIV reverse transcriptases (RT). Whereas the nucleoside analogs were inactive against HIV-1 in culture, the nucleotide showed good activity not only against wild-type and recombinant HIV RT (IC₅₀ = 4.7, 6.9 μ M), but also against the M184I and M184V mutants (IC₅₀ = 6.1, 6.9 μ M) in cell-free assays. Published by Elsevier Ltd.

Acquired immune deficiency syndrome (AIDS) has rapidly become one of the major causes of death in the world. It is estimated that over 40 million people have developed human immunodeficiency virus (HIV) infections, which is the causative agent of AIDS.¹ In 1985, 3'-azido-3'-deoxythymidine (AZT) was approved as the first synthetic nucleoside to inhibit the replication of HIV. Since then, a number of other synthetic nucleoside analogs have been proven to be effective against HIV. After cellular phosphorylation to the triphosphate form by cellular kinases, the nucleotides are incorporated into a growing strand of viral DNA and cause chain termination due to the absence of the 3'-hydroxyl group.

Despite the enormous success of nucleoside based therapy of HIV infection, there is still no cure for AIDS. One reason is that the prolonged clinical use of nucleoside analogs gives rise to resistant viruses that contain mutations in the RT.² For example, the M184V/I mutation in HIV-1 RT is associated with high level resistance to lamivudine (3TC) and emtricitabine (FTC). Structural studies suggest that the mechanism of resistance of HIV-1 RT carrying the M184V/I mutation involves steric hindrance, which would prevent further incorporation of nucleoside analogs such as 3TC and FTC in the nucleotide forms.³



We postulated that the more rigid and smaller cyclobutyl ring would enable the nucleoside analog to fit into the more sterically hindered active site of RT containing the M184V/I mutants. Nucleoside analogs of this type received a great deal of attention several years ago with the discovery of naturally occurring Oxetanocin A, which shows activity against HIV and Lobucavir (Cyclobut-G) with activity against HBV. However, virtually all of the reported derivatives possess the

Keywords: Antiviral; Anti-HIV; Nucleoside; Analogs; Resistance; Synthesis.

^{*} Corresponding author. E-mail: dliotta@emory.edu

⁰⁹⁶⁰⁻⁸⁹⁴X/\$ - see front matter Published by Elsevier Ltd. doi:10.1016/j.bmcl.2007.03.094

2'3'-bis-hydroxyl motif that enables them to be phosphorylated and incorporated into growing strands of DNA. We were interested in preparing a series of 2'substituted cyclobutyl nucleosides that only have the 3'-hydroxymethyl for phosphorylation, but not the 2'hydroxymethyl motif. We reasoned that these nucleoside analogs could fit into the more sterically hindered active site of M184I/V mutant forms of RT.

In this paper, we report the synthesis and biological evaluation of 2'-substituted cyclobutyl nucleosides as potential anti-HIV agents. To elucidate the mechanism of action of these novel cyclobutyl nucleosides, a triphosphate derivative **21** was also synthesized and evaluated against wild-type and mutant HIV-1 RT.

The 5-fluoro-1-[*cis*-3-(hydroxymethyl)-cyclobutyl]-cytosine 1 was synthesized using a reported procedure.⁴ As shown in Scheme 1, reduction of the cyclobutanone 4 with L-Selectride in THF solution gave *cis*-compound **5**, which was converted to *trans*-(3-benzyloxymethyl)cyclobutanol **6** via Mitsunobu reaction followed by hydrolysis of the resulting ester. Cyclobutanol **6** reacted with N^3 -benzoyl-5-fluorouracil under Mitsunobu conditions to give nucleoside **7** which was deprotected to give 5-fluorouracil nucleoside **8** in moderate yield. Finally, compound **8** was converted to the corresponding 5-fluorocytosine derivative **1** by the procedure shown in Scheme 2.

Fluorine as a substituent is isosteric with hydrogen; therefore, it should not affect the spatial disposition of atoms in the molecule. On the other hand, the physico-chemical properties of a fluorine atom can, due to its high electron negativity, profoundly affect the electrostatic properties of the bonds around it, thereby influencing both the conformation of the four-membered ring and the innate strength of the bonds.



Scheme 1. Synthesis of 5-fluoro-1-[cis-3-(hydroxymethyl)-cyclobutyl]-uracil.



Scheme 2. Synthesis of 2'-substituted cyclobutyl 5-fluorocytidine analogs.



Scheme 3. Synthesis of 3-benzyloxymethyl-2-methylcyclobutanol.

In the synthesis of 2'-fluoro-substituted cyclobutyl nucleosides, we found electrophilic fluorination with Selectfluor to be the most efficient method to introduce fluorine in the cyclobutanone 4.⁵ As shown in Scheme 2, the cyclobutanone 4 was first deprotonated by LDA, followed by lithium enolate quenching with TMSCl to afford the silvl enol ether 9.6 This silvl enol ether was then allowed to react with Selectfluor to give a 3:1 mixture of inseparable diastereomers 10. The crude mixture was reduced by L-Selectride followed by chromatography to isolate pure diastereomer 11 in good yield. Mesylation of 11 gave compound 12, which then was coupled with N^3 -(4-methoxybenzyl)-5-fluorouracil under basic conditions to give 53% of nucleoside 13. Removal of both the *p*-methoxylbenzyl and benzyl groups by aluminum trichloride afforded compound 14 in 80% yield. The stereochemistry of 14 was confirmed by X-ray crystal structure analysis.7 Conversion of 14 to 5-fluoro-1-[trans-2-fluoro-cis-3-(hydroxylmethyl)-cyclobutyl]cytosine 2 was achieved in the standard three-step process as shown in Scheme 2.

To compare the electronic properties of the 2'-substituted analogs, the 2'-methylcyclobutyl nucleoside was synthesized and evaluated. As shown in Scheme 3, a keteniminium salt was used as the key intermediate to form the cyclobutanone.⁸ The keteniminium triflate generated from N,N-dimethylpropionamide in situ reacted with allyl benzyl ether to give the intermediate cyclobutaniminium salt which is hydrolyzed to provide cyclobutanone 15 as the major diastereomer with the methyl group *trans* to the benzyl group (dr = 9:1). Reduction of the cyclobutanone 15 gave primarily one diastereomer 16 with the methyl group and the hydroxyl group cis to each other as confirmed by ¹H NOE analysis. The remainder of the synthesis of 5-fluoro-1-[trans-2'methyl-cis-3'-(hydroxymethyl)cyclobutyl]cytosine 3 is shown in Scheme 2.

Although they were not found to be toxic, unfortunately, none of the nucleosides 1, 2, and 3 showed significant anti-HIV activity up to 100 μ M in primary human lymphocytes infected with HIV-1 (strain LAI). To elucidate the mechanism of the nucleotides incorporating into the viral DNA chain, the triphosphate of nucleoside 1 was synthesized according to Scheme 4.

The monophosphate **20** was generated by the reaction of the nucleoside with phosphorus oxychloride using trimethylphosphate as the solvent. The monophosphate **20** was activated as its morphine phosphoramidate, which was subsequently combined with nucleophilic pyrophosphate to provide triphosphate **21** (Scheme 4).^{9–11}

Although the previously described anti-HIV studies demonstrated that compound 1 was not active up to



Scheme 4. Synthesis of triphosphate of compound 1.

Table 1. Comparison of inhibition of HIV RT in cell-free ass	ays
---	-----

HIV RT ^a	Inhibition of RT activity $(IC_{50}, \mu M)$	
	3TC-TP	Compound 21
Recombinant HIV RT (WT)	3.0	4.7
HIV RT (WT)	6.5	6.9
HIV RT (M184I)	>10	6.1
HIV RT (M184V)	>10	6.9

^a All the HIV RT used, except the recombinant RT, was obtained from viral lysates from PBM cell infected with respective HIV.

100 μ M, its triphosphate **21** exhibited comparable anti-HIV activity to 3TC-TP against recombinant HIV RT and wild-type HIV RT (IC₅₀ = 4.7, 6.9 μ M). Furthermore, the triphosphate showed also very good activity against M184I and M184V mutant RT (IC₅₀ = 6.1, 6.9 μ M), which were not inhibited by 3TC-TP. The results suggest that the cyclobutyl nucleotide can be incorporated into the DNA chains of HIV RT and M184M/V mutants to terminate the DNA elongation.

All the biochemical results were obtained according to the assay described by Eriksson et al.¹⁰ and are shown in Table 1.

In conclusion, several 2'-substituted cyclobutyl nucleosides were synthesized and evaluated as anti-HIV agents. Although the cyclobutyl nucleosides were not active against HIV, the triphosphate form of one of them was quite active against wild-type and M184V or M184I HIV RT. This suggests that the nucleosides are not being phosphorylated by the cellular kinases. It appears that the cellular kinases cannot recognize the modified nucleoside analogs due to their structural and conformational differences from the natural nucleoside substrates. Our future work will be focused on the synthesis of phosphate prodrugs of various cyclobutyl nucleoside analogs to circumvent the problems with phosphorylation.

Acknowledgments

This work was supported by NIH Grants 2R37AI-28731 (D.C.L.), 1R37AI-41890 (R.F.S.), Emory's CFAR Grant 5P30-AI150409, and the Department of Veterans Affairs (R.F.S.). We thank Dr. R. Pai and Kim L. Rapp for performing the RT assays.

References and notes

- Pani, A.; Loi, A. G.; Mura, M.; Marceddu, T.; La Colla, P.; Marongiu, M. E. Curr. Drug Targets Infect. Disord. 2002, 2, 17.
- Schuurman, R.; Nijhuis, M.; van Leeuwen, R.; Schipper, P.; de Jong, D.; Collis, P.; Danner, S. A.; Mulder, J.; Loveday, C. J. Infect. Dis. 1995, 171, 1411.
- Gao, H. Q.; Boyer, P. L.; Sarafianos, S. G.; Arnold, E.; Hughes, S. H. J. Mol. Bio. 2000, 300, 403.
- (a) Kaiwar, V.; Reese, C. B.; Gray, E. J.; Neidle, S. J. Chem. Soc. Perkin Trans. 1 1995, 18, 2281; (b) Frieden, M.; Giraud, M.; Reese, C. B.; Song, Q. J. Chem. Soc. Perkin Trans. 1 1998, 17, 2827; (c) He, W.; Togo, H.; Ogawa, H.; Yokoyama, M. Heteroat. Chem. 1997, 8, 411.
- (a) Nyffeler, P. T.; Durón, S. G.; Burkart, M. D.; Vincent, S. P.; Wong, C.-H. Angew. Chem. Int. Ed. 2005, 44, 192;
 (b) Singh, R. P.; Shreeve, J. M. Acc. Chem. Res. 2004, 37,

31; (c) Stavber, S.; Jereb, M.; Zupan, M. Synthesis 2002, 17, 2609; (d) Stavber, G.; Zupan, M.; Jereb, M.; Stavber, S. Org. Lett. 2004, 6, 4973.

- 6. Vidal, J.; Huet, F. J. Org. Chem. 1988, 53, 611.
- 7. X-ray structure of 5-fluoro-1-[*trans*-2-fluoro-*cis*-3-(hydroxymethyl)cyclobutyl]uracil **14** (CCDC 640733):



- Falmagne, J. B.; Schmit, C.; Escudero, J.; Vanlierde, H.; Ghosez, L. Org. Synth. 1990, 69, 199.
- 9. (a) Moffatt, J. G.; Khorana, H. G. *Can. J. Chem.* **1961**, *39*, 649; (b) Moffatt, J. G. *Can. J. Chem.* **1964**, *42*, 599.
- 10. Eriksson, B. F.; Chu, C. K.; Schinazi, R. F. Antimicrob. Agents Chemother. 1989, 33, 1729.
- 11. Compound **21**: ¹H NMR (D₂O, 400 MHz): δ 1.22 (t, J = 7.2 Hz, 36H), 2.14 (m, 2H), 2.49 (m, 3H), 3.08 (m, 2H), 3.19 (q, J = 7.2 Hz, 24H), 4.64 (m, 1H), 8.12 (d, J = 7.2 Hz, 1H). ³¹P NMR (D₂O, referenced to H₃PO₄, 162 MHz): δ -22.9 (1P), -10.5 (2P).